Subree Subramanian
,
Credentials
MS, PhD

Professor, Division of Basic and Translational Research
Biography

Bio

Dr. Subramanian completed his postdoctoral fellowship at Stanford University and joined the faculty at the University of Minnesota in 2007. Dr. Subramanian has established an internationally recognized cancer research program focused on deciphering the molecular mechanisms of immune evasion in cancer. His current research focuses on understanding how cancer cells and gut microbiome manipulate the anti-tumor immune response in colorectal cancer. Specifically, Dr. Subramanian's research has shed light on how cancer cells and the gut microbiome collaborate to suppress the immune response in patients with colorectal cancer. Dr. Subramanian and his team have revealed a previously unknown mechanism affecting T cell costimulation in colorectal cancer by identifying the immune suppression mediated by cancer- secreted exosomes. These findings have immense clinical relevance, offering new insights into treating advanced-stage colorectal cancer.

Dr. Subramanian's extensive publication record, including over 120 peer-reviewed articles, attests to his high-quality research and impact. He serves as the section Editor-in-Chief of the journal Vaccines and the Associate section Editor-in-Chief of Cancers. As a co-founder and Chief Scientific Officer of EV Therapeutics Inc., Dr. Subramanian is at the forefront of developing clinical-grade engineered exosomes to treat advanced-stage colorectal cancer patients. Moreover, as a leader in his field, Dr. Subramanian is dedicated to training the next generation of scientists and making a difference in people's lives. Beyond his research and teaching, Dr. Subramanian is committed to giving back to his community, a testament to his dedication to scientific advancement and social responsibility.

ACADEMIC APPOINTMENTS: 

PUBLICATIONS

Pubmed link

Recent publications:

  1. Zhao X, Yuan C, Wangmo D, Subramanian S. Tumor-secreted extracellular vesicles regulate T-cell costimulation and can be manipulated to induce tumor-specific T-cell responses. Gastroenterology 2021 161: 560-574
  2. Wangmo D, Premsrirut PK, Yuan C, Morris WS, Zhao X and Subramanian S. Loss of ACKR4 in tumor cells dysregulates dendritic cell migration to tumor-draining lymph nodes and T-cell priming. Cancers 2021. 7;13(19):5021.
  3. Nair, AA Tang X, Thompson KJ, Kalari KR, Subramanian S. MicroRNA response elements frequency identifies dysregulation of MAPK signaling in triple-negative breast cancer. Doi: http://dx.doi.org/10.1101/817098. iScience 2020 23(6):101249
  4. Yuan C, Graham M, Subramanian S. Mucosal Microbiota and Metabolome along the Intestinal Tract Reveal a Location-Specific Relationship. mSystems 2020 5(3):e00055-20 5. Zhao X, Kassaye B, Wangmo D, Lou E, Subramanian S. Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors. iScience 2020 23(5):101056
Contact

Contact

Address

Department of Surgery
420 Delaware St SE MMC 195
Minneapolis, MN 55455

Administrative Contact

Kelli Tourand |  612-624-4581 | toura018@umn.edu